Foghorn Therapeutics Appoints New Board Members

Foghorn Therapeutics ( (FHTX) ) just unveiled an announcement.

On April 25, 2025, Foghorn Therapeutics appointed Stuart Duty and Neil J. Gallagher, M.D., Ph.D., to its Board of Directors, effective May 1, 2025. Both directors are recognized as independent under Nasdaq standards. Mr. Duty will serve on the Audit Committee, while Dr. Gallagher will join the Science Committee. Their appointments align with Foghorn’s strategic goals to enhance its pipeline and compliance with Nasdaq’s audit committee requirements. The appointments are expected to leverage their extensive industry experience to advance Foghorn’s clinical and preclinical developments in oncology.

Spark’s Take on FHTX Stock

According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral.

Foghorn Therapeutics faces significant financial instability, reflected in ongoing losses and negative equity. Technical indicators suggest bearish momentum, posing additional risks. However, promising advancements in drug development and strategic collaborations provide a positive outlook, partially offsetting the financial challenges. Valuation remains a concern due to lack of profitability and dividend yield.

To see Spark’s full report on FHTX stock, click here.

More about Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage biotechnology company focused on developing a new class of medicines that target genetically determined dependencies within the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control® platform, the company is advancing multiple product candidates in oncology.

YTD Price Performance: -8.50%

Average Trading Volume: 138,046

Technical Sentiment Signal: Buy

Current Market Cap: $233.6M

Learn more about FHTX stock on TipRanks’ Stock Analysis page.